Clinical trialNCT01203514CompletedPhase 2/PHASE3Interventional

The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants

SponsorNICHD Neonatal Research NetworkEnrollment318Anemia, NeonatalInfant, Low Birth WeightInfant, NewbornInfant, PrematureInfant, Small for Gestational Age

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study tested the safety and efficacy of transfusing erythropoietin (Epo) and iron in infants of \<1,250g birth weight. For infants 401-1,000g birth weight, we tested whether early erythropoietin (Epo) and iron therapy would decrease the number of transfusions received. For infants 1,001-1,250g birth weight, we tested whether early erythropoietin (Epo) and iron therapy would decrease the percentage of infants who received any transfusions.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Ann R. Stark, MD
Brigham and Women's Hospital
Principal Investigator
clinicaltrials.gov ↗
Barbara J. Stoll, MD
Emory University
Principal Investigator
clinicaltrials.gov ↗
Edward F. Donovan, MD
Children's Hospital Medical Center, Cincinnati
Principal Investigator
clinicaltrials.gov ↗
James A. Lemons, MD
Indiana University
Principal Investigator
clinicaltrials.gov ↗
Raymond Bain, PhD
George Washington University
Principal Investigator
clinicaltrials.gov ↗
Richard A. Ehrenkranz, MD
Yale University
Study Director
clinicaltrials.gov ↗
Robin K. Ohls, MD
University of New Mexico
Study Director
clinicaltrials.gov ↗
Seetha Shankaran, MD
Wayne State University
Principal Investigator
clinicaltrials.gov ↗
Sheldon B. Korones, MD
University of Tennessee
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Yale University
New Haven, Connecticut, United States
George Washington University
Washington D.C., District of Columbia, United States
Emory University
Atlanta, Georgia, United States
Indiana University
Indianapolis, Indiana, United States
Harvard University
Cambridge, Massachusetts, United States
Wayne State University
Detroit, Michigan, United States
University of New Mexico
Albuquerque, New Mexico, United States
Cincinnati Children'S Medical Center
Cincinnati, Ohio, United States
University of Tennessee
Memphis, Tennessee, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Epoetin alfa →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Aug 1997
Primary completion: 31 Aug 1998
Completion: 31 Aug 2000
Last update posted: 26 Sept 2017
Registered enrollment: 318
Registry id: NCT01203514

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.